Vunakizumab effectively treats moderate-to-severe plaque psoriasis across diverse baseline disease features

Effective management of plaque psoriasis, a chronic inflammatory skin condition, often requires therapies that can overcome variability in patient presentation. Interleukin-17 (IL-17) inhibitors represent a key therapeutic class, targeting the IL-17 pathway crucial for psoriatic inflammation. However, it's been hypothesized that baseline disease characteristics, such as duration or severity, might influence the efficacy of these treatments. Understanding if an IL-17 inhibitor maintains consistent efficacy across diverse disease features is vital for optimizing treatment strategies and ensuring broad applicability, addressing a critical gap in personalized psoriasis care.

This post hoc analysis utilized data from a phase III trial (NCT04839016) involving 690 patients with moderate-to-severe plaque psoriasis. Patients were randomized to receive vunakizumab (n=461) or placebo (n=229). The study aimed to explore vunakizumab's efficacy when patients were stratified by various baseline disease features, including duration of psoriasis, initial PASI score, body surface area (BSA) involvement, and static physician's global assessment (sPGA) score. Primary endpoints included the proportions of patients achieving PASI 75, PASI 90, PASI 100, and sPGA 0/1 responses at weeks 4, 8, 12, 24, and 52.

Vunakizumab demonstrated robust efficacy across all assessed baseline disease features. At week (W) 12, the proportions of patients achieving PASI 75, PASI 90, PASI 100, and sPGA 0/1 responses were significantly higher in the vunakizumab group compared to the placebo group. This superior response was observed irrespective of the duration of psoriasis, baseline PASI score, BSA involvement, or sPGA score. Similar trends of higher treatment response rates in the vunakizumab group were also evident at W4 and W8, consistently showing efficacy across diverse patient profiles. This consistent benefit extended to W24. However, at W52, treatment responses were almost indistinguishable between patients continuously receiving vunakizumab and those who switched from placebo to vunakizumab, regardless of disease duration and severity. This suggests a sustained benefit for those who initiated vunakizumab, with catch-up for those who switched. > Vunakizumab significantly improved PASI 75, PASI 90, PASI 100, and sPGA 0/1 responses at W12, W4, W8, and W24, consistently outperforming placebo regardless of baseline psoriasis duration, severity, or body surface area involvement.